BASEL, SWITZERLAND--(Marketwire - April 17, 2012) -
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Basel, Switzerland, April 17, 2012 - Basilea Pharmaceutica Ltd. (SIX: BSLN)
shareholders approve all Board of Directors' proposals at this year's
Today the shareholders of Basilea approved the annual report, the financial
statements and consolidated financial statements for the business year
discharged the members of the Board of Directors and Management.
also approved carrying forward the accumulated deficit.
Mr. Hans-Beat Gürtler and Prof. Daniel Lew were re-elected to the
Directors for a term of three years each.
Shareholders re-elected PricewaterhouseCoopers AG, Basel, as Statutory
for the audit of the stand-alone and the consolidated financial statements
the business year 2012.
The Board of Directors confirmed Mr. Werner Henrich as Chairman of the
Directors and Mr. Hans-Beat Gürtler as Vice-Chairman.
At the Ordinary General Meeting for the financial year 2011, 53% of the
share capital of the company were represented.
In his presentation to shareholders, Dr. Anthony Man, Chief Executive
commented: "Over the last year Basilea has built the foundation for two
potential regulatory filings. We now have topline data from our large U.S.
III HANDEL trial with oral alitretinoin that forms the basis of a potential
future U.S. filing and our partnership discussions. For ceftobiprole,
for treatment of severe pneumonia in the hospital, we are moving forward
our European marketing application planned for the second half of the year
and are actively discussing potential partnerships for this drug addressing
resistant bacterial infections. We continue to advance the phase III
isavuconazole in addition to our two innovative phase I compounds. We are
focused on achieving clinical and regulatory milestones for our key
value drivers, optimizing the value of our assets through potential
partnerships, and steadily increasing sales in Toctino."
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and
the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research
development operations of its Swiss subsidiary Basilea Pharmaceutica
International Ltd. the company focuses on innovative pharmaceutical
the therapeutic areas of bacterial infections, fungal infections, oncology
skin diseases, targeting the medical challenge of rising resistance and
non-response to current treatment options in the hospital and specialty
setting. The Basilea group includes affiliates in European countries as
Basilea is currently marketing Toctino® (oral alitretinoin), approved
European countries, Canada and Israel for the treatment of adults with
chronic hand eczema unresponsive to potent topical corticosteroids, in
Finland, France, Germany, Iceland, Norway, Switzerland and the United
and has appointed distributors for Toctino® in other selected European
Canada, Israel, Mexico and the Republic of Korea. In the U.S., oral
is an investigational drug. Topline data from the U.S. phase III study
on oral alitretinoin have been recently reported. The results are
with previous randomized international studies.
For its phase III compound isavuconazole, a potential best-in-class azole
antifungal for the treatment of life-threatening invasive fungal
company has entered into a license, co-development and co-promotion
with Astellas Pharma Inc.
In addition, Basilea is developing ceftobiprole, a late-stage novel
(methicillin-resistant Staphylococcus aureus) broad-spectrum cephalosporin
antibiotic, for the first-line treatment of potentially life-threatening
resistant bacterial infections. Ceftobiprole has a broad coverage of both
Gram-positive bacteria, including MRSA, and many clinically important
bacteria such as Pseudomonas spp.
Basilea's BAL30072, a novel investigational antibiotic for the treatment of
Gram-negative infections, and the oncology drug candidate BAL101553
for the treatment of drug-resistant cancers are in phase I clinical
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
or achievements of Basilea Pharmaceutica Ltd. to be materially different
any future, anticipated results, performance or achievements expressed or
implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is
providing this communication as of this date and does not undertake to
any forward-looking statements contained herein as a result of new
future events or otherwise.
This press release can be downloaded from www.basilea.com.
Press release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE